SOST

SOST Molekülinformation

Englischer NameSclerostinAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel6Target-AliasSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameSclerostin
Target-AliasSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel6
Höchste Forschungs- und EntwicklungsphaseApproved

SOST Produktliste

  • Attribut

    Protein (4)

  • Produktbibliothek

    Online (4)

  • Spezies

    Human (2)Mouse (2)

  • Etikett

    His Tag (3)His Tag & Avi Tag (1)

  • Marker

    Unconjugated (2)Biotin-labeled (2)

SOST Molekülhintergrund

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST Molekülalias

SOST,VBCH

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgBone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
Details
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) LtdOsteogenesis Imperfecta
Details
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co LtdOsteoporosis, Postmenopausal
Details
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And CompanyOsteoporosis; Osteoporosis, Postmenopausal
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation